# Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

> **NCT05304715** · PHASE2 · COMPLETED · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 44 (actual)

## Conditions studied

- Clostridioides Difficile Infection
- Stool Microbiome
- Organ Dysfunction Syndrome
- Clostridioides Difficile Infection Recurrence
- Mortality

## Interventions

- **DRUG:** Bezlotoxumab
- **DRUG:** Normal saline 0.9% or 5% dextrose water

## Key facts

- **NCT ID:** NCT05304715
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2023-06-04
- **Final completion:** 2023-06-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304715, "Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05304715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*